Reply

We thank Ozaras et  al for their thoughtful comments on our article, “The risk of Hepatitis B Reactivation in HBsAg-Negative and Anti-HBc–Positive Patients Receiving Tumor Necrosis Factor Antagonists.” They pointed out that the cohort of hepatitis B surface antigen (HBsAg)-/antibody to hepatitis B core antigen (anti-HBc)+ patients was a heterogeneous group and those who were negative for antibody to hepatitis B surface antigen were at risk of HBV reactivation when they received potent immunosuppressive therapy such as rituximab.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research

Related Links:

CONCLUSIONS: These findings suggest that most persons who inject drugs in Wisconsin are susceptible to HAV infection and that most persons aged ≥35 who inject drugs are susceptible to HBV infection. In addition to routine vaccination of children, targeted hepatitis vaccination programs should focus on adults who inject drugs to help prevent future infections. PMID: 31539482 [PubMed - as supplied by publisher]
Source: Public Health Reports - Category: International Medicine & Public Health Tags: Public Health Rep Source Type: research
This study was aimed to assess the association of this serological pattern with hepatocellular carcinoma (HCC) in patients with CHB.MethodsIn this cross-section study, 206 CHB patients with coexistence of HBsAg/anti-HBs and 206 CHB patients with HBsAg alone were included to evaluate the risk of HCC development by logistic regression analysis. In addition, a retrospective cohort of 260 patients with CHB was recruited to estimate the cumulative incidence of HCC by Kaplan–Meier analysis.ResultsThe serological pattern of coexistence of HBsAg/anti-HBs, with high levels of (“High”) HBsAg/low levels of (“L...
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
Conclusion: Several health maintenance aspects are inadequately addressed by GIs and PCPs, in part because of conflicting perceptions of responsibility. Clear guidelines and better GI/PCP communication are required to ensure effective health maintenance for patients with IBD. PMID: 31528131 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research
This study demonstrated, for the first time, that ADAR1 plays an antiviral role against HBV infection by increasing the level of miRNA-122 in hepatocytes.
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Microbiology Source Type: research
Chronic hepatitis B virus (HBV) infection is a major global health burden affecting around 257 million people worldwide. The consequences of chronic HBV infection include progressive liver damage, liver cirrhosis, and hepatocellular carcinoma. Although current direct antiviral therapies successfully lead to suppression of viral replication and deceleration of liver cirrhosis progression, these treatments are rarely curative and patients often require a life-long therapy. Based on the ability of the immune system to control HBV infection in at least a subset of patients, immunotherapeutic approaches are promising treatment ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractIn the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection who achieved SVR in short term. HCC occurrence was more often observed in patientswith previous HCC history. We found occurrence of HCC in 178 (29.6%) of 602 patientswith previous HCC history (15.4  months mean follow-up post-DAA initiation) but, in contrast, in only 604 (1.3%) of 45,870 patientswithout previous HCC ...
Source: Hepatology International - Category: Infectious Diseases Source Type: research
Authors: Bahaji Azami NL, Sun M Abstract Goji berry, Lycium barbarum, has been widely used in traditional Chinese medicine (TCM), but its properties have not been studied until recently. The fruit is a major source of zeaxanthin dipalmitate (ZD), a xanthophyll carotenoid shown to benefit the liver. Liver disease is one of the most prevalent diseases in the world. Some conditions, such as chronic hepatitis B virus, liver cirrhosis, and hepatocellular carcinoma, remain incurable. Managing them can constitute an economic burden for patients and healthcare systems. Hence, development of more effective pharmacological d...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Abstract Persistent coinfection with the hepatitis B/D viruses (HDV) represents the most severe form of viral hepatitis. Hepatitis D often leads to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. The current treatment options are limited as only pegylated interferon-alpha (PEG-IFNa) has efficacy against HDV. However, treatment response is still unsatisfactory with 25-40% HDV RNA suppression after 1-2 years. In addition, late HDV RNA relapses have been described during long-term follow-up. Fortunately, new treatment options for patients with chronic hepatitis delta are now on the horizon. The...
Source: AIDS Reviews - Category: Infectious Diseases Authors: Tags: AIDS Rev Source Type: research
[Leadership] The Hepatitis Zero Nigerian Commission, a Global Eradication Project initiative, has said that Nigeria is estimated to have the highest cases of Hepatitis B in the World at 12.2 per cent which translates to about 20 to 30 million infected by the virus.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Publication date: October 2019Source: American Journal of Preventive Medicine, Volume 57, Issue 4Author(s):
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
More News: Gastroenterology | Hepatitis | Hepatitis B | Rituxan